The Experts below are selected from a list of 87 Experts worldwide ranked by ideXlab platform
Jungwon Hwang - One of the best experts on this subject based on the ideXlab platform.
-
randomized clinical trial on the preventive effects of Butylscopolamine on early postoperative catheter related bladder discomfort
Surgery, 2015Co-Authors: Karam Nam, Young-tae Jeon, Hee Pyoung Park, Jeonghwa Seo, Jung Hee Ryu, Taeseung Lee, Jungwon HwangAbstract:Background Postoperative catheter-related bladder discomfort (CRBD) can be a distressing complication for patients in whom a urinary catheter was inserted during an operation. Our randomized, dual-center, clinical trial investigated the effects of Butylscopolamine on the prevention of postoperative CRBD in patients undergoing various operations. Methods Adult male patients undergoing elective operations requiring intraoperative urinary catheterization under general anesthesia were enrolled. They were assigned randomly to 2 groups: The Butylscopolamine group (n = 49) received 20 mg of Butylscopolamine intravenously immediately before the end of the operation; no medication was given for prevention of CRBD in the control group (n = 50). The presence and severity of CRBD were assessed at 1, 2, and 6 hours postoperatively. Adverse effects of Butylscopolamine were also examined. Results The overall incidence of CRBD was less in the Butylscopolamine group than in the control group (31% vs 66%, respectively; P = .001). The incidence of CRBD at 1, 2, and 6 hours postoperatively was also less in the Butylscopolamine group (P = .006, .04, and .048, respectively). In addition, the average severity of CRBD for 6 hours postoperatively was significantly less in the Butylscopolamine group than in the control group (median, 0 [interquartile range, 0-17] vs 22 [interquartile range, 0-47], respectively; P = .002). Adverse effects were comparable between the 2 groups. Conclusion Intravenous administration of Butylscopolamine at the end of an operation decreases effectively the incidence and severity of early postoperative CRBD without adverse effects.
-
efficacy of Butylscopolamine for the treatment of catheter related bladder discomfort a prospective randomized placebo controlled double blind study
BJA: British Journal of Anaesthesia, 2013Co-Authors: Jung Hee Ryu, Jungwon Hwang, Hee Pyoung Park, J Lee, Jeonghwa Seo, Young-tae JeonAbstract:Background Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of Butylscopolamine in treating CRBD after urological surgeries. Methods Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the Butylscopolamine group (n=28) was administered Butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results The severity of CRBD observed in the Butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the Butylscopolamine group, P Conclusion Butylscopolamine 20 mg administered i.v. after complaining CRBD during recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.
Young-tae Jeon - One of the best experts on this subject based on the ideXlab platform.
-
randomized clinical trial on the preventive effects of Butylscopolamine on early postoperative catheter related bladder discomfort
Surgery, 2015Co-Authors: Karam Nam, Young-tae Jeon, Hee Pyoung Park, Jeonghwa Seo, Jung Hee Ryu, Taeseung Lee, Jungwon HwangAbstract:Background Postoperative catheter-related bladder discomfort (CRBD) can be a distressing complication for patients in whom a urinary catheter was inserted during an operation. Our randomized, dual-center, clinical trial investigated the effects of Butylscopolamine on the prevention of postoperative CRBD in patients undergoing various operations. Methods Adult male patients undergoing elective operations requiring intraoperative urinary catheterization under general anesthesia were enrolled. They were assigned randomly to 2 groups: The Butylscopolamine group (n = 49) received 20 mg of Butylscopolamine intravenously immediately before the end of the operation; no medication was given for prevention of CRBD in the control group (n = 50). The presence and severity of CRBD were assessed at 1, 2, and 6 hours postoperatively. Adverse effects of Butylscopolamine were also examined. Results The overall incidence of CRBD was less in the Butylscopolamine group than in the control group (31% vs 66%, respectively; P = .001). The incidence of CRBD at 1, 2, and 6 hours postoperatively was also less in the Butylscopolamine group (P = .006, .04, and .048, respectively). In addition, the average severity of CRBD for 6 hours postoperatively was significantly less in the Butylscopolamine group than in the control group (median, 0 [interquartile range, 0-17] vs 22 [interquartile range, 0-47], respectively; P = .002). Adverse effects were comparable between the 2 groups. Conclusion Intravenous administration of Butylscopolamine at the end of an operation decreases effectively the incidence and severity of early postoperative CRBD without adverse effects.
-
efficacy of Butylscopolamine for the treatment of catheter related bladder discomfort a prospective randomized placebo controlled double blind study
BJA: British Journal of Anaesthesia, 2013Co-Authors: Jung Hee Ryu, Jungwon Hwang, Hee Pyoung Park, J Lee, Jeonghwa Seo, Young-tae JeonAbstract:Background Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of Butylscopolamine in treating CRBD after urological surgeries. Methods Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the Butylscopolamine group (n=28) was administered Butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results The severity of CRBD observed in the Butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the Butylscopolamine group, P Conclusion Butylscopolamine 20 mg administered i.v. after complaining CRBD during recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.
Marco J Bruno - One of the best experts on this subject based on the ideXlab platform.
-
oxygen dependent delayed fluorescence of protoporphyrin ix measured in the stomach and duodenum during upper gastrointestinal endoscopy
Journal of Biophotonics, 2019Co-Authors: Louisa J D Van Dijk, Rinse Ubbink, Luke G Terlouw, Desiree Van Noord, Marco J BrunoAbstract:textabstractProtoporphyrin IX-triplet state lifetime technique (PpIX-TSLT) is a method used to measure oxygen (PO2) in human cells. The aim of this study was to assess the technical feasibility and safety of measuring oxygen-dependent delayed fluorescence of 5-aminolevulinic acid (ALA)-induced PpIX during upper gastrointestinal (GI) endoscopy. Endoscopic delayed fluorescence measurements were performed 4 hours after oral administration of ALA in healthy volunteers. The ALA dose administered was 0, 1, 5 or 20 mg/kg. Measurements were performed at three mucosal spots in the gastric antrum, duodenal bulb and descending duodenum with the catheter above the mucosa and while applying pressure to induce local ischemia and monitor mitochondrial respiration. During two endoscopies, measurements were performed both before and after intravenous administration of Butylscopolamine. Delayed fluorescence measurements were successfully performed during all 10 upper GI endoscopies. ALA dose of 5 mg/kg showed adequate signal-to-noise ratio (SNR) values >20 without side effects. All pressure measurements showed significant prolongation of delayed fluorescence lifetime compared to measurements performed without pressure (P <.001). Measurements before and after administration of Butylscopolamine did not differ significantly in the duodenal bulb and descending duodenum. Measurements of oxygen-dependent delayed fluorescence of ALA-induced PpIX in the GI tract during upper GI endoscopy are technically feasible and safe.
Jung Hee Ryu - One of the best experts on this subject based on the ideXlab platform.
-
randomized clinical trial on the preventive effects of Butylscopolamine on early postoperative catheter related bladder discomfort
Surgery, 2015Co-Authors: Karam Nam, Young-tae Jeon, Hee Pyoung Park, Jeonghwa Seo, Jung Hee Ryu, Taeseung Lee, Jungwon HwangAbstract:Background Postoperative catheter-related bladder discomfort (CRBD) can be a distressing complication for patients in whom a urinary catheter was inserted during an operation. Our randomized, dual-center, clinical trial investigated the effects of Butylscopolamine on the prevention of postoperative CRBD in patients undergoing various operations. Methods Adult male patients undergoing elective operations requiring intraoperative urinary catheterization under general anesthesia were enrolled. They were assigned randomly to 2 groups: The Butylscopolamine group (n = 49) received 20 mg of Butylscopolamine intravenously immediately before the end of the operation; no medication was given for prevention of CRBD in the control group (n = 50). The presence and severity of CRBD were assessed at 1, 2, and 6 hours postoperatively. Adverse effects of Butylscopolamine were also examined. Results The overall incidence of CRBD was less in the Butylscopolamine group than in the control group (31% vs 66%, respectively; P = .001). The incidence of CRBD at 1, 2, and 6 hours postoperatively was also less in the Butylscopolamine group (P = .006, .04, and .048, respectively). In addition, the average severity of CRBD for 6 hours postoperatively was significantly less in the Butylscopolamine group than in the control group (median, 0 [interquartile range, 0-17] vs 22 [interquartile range, 0-47], respectively; P = .002). Adverse effects were comparable between the 2 groups. Conclusion Intravenous administration of Butylscopolamine at the end of an operation decreases effectively the incidence and severity of early postoperative CRBD without adverse effects.
-
efficacy of Butylscopolamine for the treatment of catheter related bladder discomfort a prospective randomized placebo controlled double blind study
BJA: British Journal of Anaesthesia, 2013Co-Authors: Jung Hee Ryu, Jungwon Hwang, Hee Pyoung Park, J Lee, Jeonghwa Seo, Young-tae JeonAbstract:Background Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of Butylscopolamine in treating CRBD after urological surgeries. Methods Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the Butylscopolamine group (n=28) was administered Butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results The severity of CRBD observed in the Butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the Butylscopolamine group, P Conclusion Butylscopolamine 20 mg administered i.v. after complaining CRBD during recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.
Hee Pyoung Park - One of the best experts on this subject based on the ideXlab platform.
-
randomized clinical trial on the preventive effects of Butylscopolamine on early postoperative catheter related bladder discomfort
Surgery, 2015Co-Authors: Karam Nam, Young-tae Jeon, Hee Pyoung Park, Jeonghwa Seo, Jung Hee Ryu, Taeseung Lee, Jungwon HwangAbstract:Background Postoperative catheter-related bladder discomfort (CRBD) can be a distressing complication for patients in whom a urinary catheter was inserted during an operation. Our randomized, dual-center, clinical trial investigated the effects of Butylscopolamine on the prevention of postoperative CRBD in patients undergoing various operations. Methods Adult male patients undergoing elective operations requiring intraoperative urinary catheterization under general anesthesia were enrolled. They were assigned randomly to 2 groups: The Butylscopolamine group (n = 49) received 20 mg of Butylscopolamine intravenously immediately before the end of the operation; no medication was given for prevention of CRBD in the control group (n = 50). The presence and severity of CRBD were assessed at 1, 2, and 6 hours postoperatively. Adverse effects of Butylscopolamine were also examined. Results The overall incidence of CRBD was less in the Butylscopolamine group than in the control group (31% vs 66%, respectively; P = .001). The incidence of CRBD at 1, 2, and 6 hours postoperatively was also less in the Butylscopolamine group (P = .006, .04, and .048, respectively). In addition, the average severity of CRBD for 6 hours postoperatively was significantly less in the Butylscopolamine group than in the control group (median, 0 [interquartile range, 0-17] vs 22 [interquartile range, 0-47], respectively; P = .002). Adverse effects were comparable between the 2 groups. Conclusion Intravenous administration of Butylscopolamine at the end of an operation decreases effectively the incidence and severity of early postoperative CRBD without adverse effects.
-
efficacy of Butylscopolamine for the treatment of catheter related bladder discomfort a prospective randomized placebo controlled double blind study
BJA: British Journal of Anaesthesia, 2013Co-Authors: Jung Hee Ryu, Jungwon Hwang, Hee Pyoung Park, J Lee, Jeonghwa Seo, Young-tae JeonAbstract:Background Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of Butylscopolamine in treating CRBD after urological surgeries. Methods Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the Butylscopolamine group (n=28) was administered Butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results The severity of CRBD observed in the Butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the Butylscopolamine group, P Conclusion Butylscopolamine 20 mg administered i.v. after complaining CRBD during recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.
